...könnte was daraus werden, kursmässig und auch was den Geschäftserfolg (Diagnostik Krebs, Alzheimer, ...) betrifft.....
Make sure you load up the chart on IMGM: http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=imgm&sid...
This is an absolutely amazing chart!! IMGM ran from nothing to over $1 earlier this year and I believe it's about to happen again. The volume earlier today could be an indication of something big about to happen.
IMGM is a high risk situation and I don't suggest anyone get involved with it unless you're looking for the 300-500% type of gains.
IMGM is involved with companies that provide a new diagnostic imaging service the can detect early signs of cancer. It's a lot like the CAT scan.
IMGM just released huge news:
One of their wholly owned subsidiaries just received regulatory approval to bill Medicare and Medicaid for their (Pet) imaging services. This is going to result in huge profits for IMGM.
IMGM's strategy and focus is dedicated to business opportunities in positron emission tomography (PET) manufacturing and the diagnosis of cancer, heart disease and neurological diseases. PET is an advanced medical diagnostic imaging procedure used by physicians in the detection of certain cancers, coronary disease and neurological disorders including Alzheimer's disease.
Companies like IMGM are extremely important today. As the cancer-cure frenzy continues, it is companies like IMGM who are presently dealing with fighting cancer.
One of every two men and one out of three women will get cancer in their lifetimes. About 565,000 Americans are expected to die of cancer in 2006. According to the National Institutes of Health, overall costs for cancer in 2005 were nearly $210 billion. These are very scary facts!!
IMGM is in positron emission tomography (PET) technology, a technology that is growing rapidly.
Being diagnosed with cancer is a scary event, but with companies like IMGM and the use of (PET) technology, a lot of valuable time and money can be saved as well as the person's life. IMGM also focuses on other dangerous diseases responsible for killing people like heart disease and neurological diseases.
IMGM specializes in using evidence based bioinformatics specifically positioned in the market to provide the maximal cost effective benefit to their joint venture partner and the community
IMGM is a factor in (PET) and ancillary molecular imaging businesses. Imagin Nuclear Partners, a wholly owned subsidiary of IMGM, is a full-service joint venture molecular imaging partner that will own, operate and administer out-patient medical diagnostic imaging centers that utilizes PET and PET/CT scanning equipment.
The demand for companies like IMGM and (PET) technology continued to grow in 2004 reaching 1 million procedures, an increase of 46% for the year. Growth should continue with procedure volume increasing 37% in 2005. By 2010, PET procedure volume should rise to 3.2 million procedures.
Make sure you do your own research on IMGM and consult a professional before making any type of investment decision.
You can learn more about IMGM at their website: http://www.imaginmolecularcorp.com